|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Cytomegalovirus and ulcerative colitis:Place of antiviraltherapy显示文摘The link between cytomegalovirus(CMV) infection and inflammatory bowel diseases remains an important subject of debate. CMV infection is frequent in ulcerative colitis(UC) and has been shown to be potentially harmful. CMV reactivation needs to be diagnosed using methods that include in situ detection of viral markers by immunohistochemistry or by nucleic acid amplification techniques. Determination of the density of infection using quantitative tools(numbers of infected cells or copies of the genome) is particularly important. Although CMV reactivation can be considered as an innocent bystander in active flareups of refractory UC, an increasing number of studies suggest a deleterious role of CMV in this situation. The presence of colonic CMV infection is possibly linked to a decreased response to steroids and other immunosuppressive agents. Some treatments, notably steroids and cyclosporine A, have been shown to favor CMV reactivation, which seems not to be the case for therapies using anti-tumor necrosis factor drugs. According to these findings, in flare-ups of refractory UC, it is now recommended to look for the presence of CMV reactivation by using quantitative tools in colonic biopsies and to treat them with ganciclovir in cases of high viral load or severe disease. | Sylvie Pillet Bruno Pozzetto Xavier Roblin | 2016 | World Journal of Gastroenterology2016，22，6： | 19 |
| 2 | Health care-associated hepatitis C virus infection显示文摘Hepatitis C virus(HCV)is a blood-borne pathogen that has a worldwide distribution and infects millions of people.Care-associated HCV infections represented a huge part of hepatitis C burden in the past via contaminated blood and unsafe injections and continue to be a serious problem of public health.The present review proposes a panorama of health care-associated HCV infections via the three mode of contamination that have been identified:(1)infected patient to non-infected patient;(2)infected patient to non-infected health careworker(HCW);and(3)infected HCW to non infected patient.For each condition,the circumstances of contamination are described together with the means to prevent them.As a whole,the more important risk is represented by unsafe practices regarding injections,notably with the improper use of multidose vials used for multiple patients.The questions of occupational exposures and infected HCWs are also discussed.In terms of prevention and surveillance,the main arm for combating care-associated HCV infections is the implementation of standard precautions in all the fields of cares,with training programs and audits to verify their good application.HCWs must be sensitized to the risk of blood-borne pathogens,notably by the use of safety devices for injections and good hygiene practices in the operating theatre and in all the invasive procedures.The providers performing exposed-prone procedures must monitor their HCV serology regularly in order to detect early any primary infection and to treat it without delay.With the need to stay vigilant because HCV infection is often a hidden risk,it can be hoped that the number of people infected by HCV via health care will decrease very significantly in the next years. | Bruno Pozzetto Meriam Memmi Olivier Garraud Xavier Roblin Philippe Berthelot | 2014 | World Journal of Gastroenterology2014，20，46： | 5 |
| 3 | Combination of corticosteroids and 5-aminosalicylates or corticosteroids alone for patients with moderate-severe active ulcerative colitis:A global survey of physicians'practice显示文摘AIM To examine treatment decisions of gastroenterologists regarding the choice of prescribing 5-aminosalycilates(5ASA) with corticosteroids(CS) versus corticosteroids alone for patients with active ulcerative colitis(UC). METHODS A cross-sectional questionnaire exploring physicians' attitude toward 5ASA + CS combination therapy vs CS alone was developed and validated. The questionnaire was distributed to gastroenterology experts in twelve countries in five continents. Respondents' agreement with stated treatment choices were assessed by standardized Likert scale. Background professional characteristics of respondents were analyzed for correlation with responses. RESULTS Six hundred and sixty-four questionnaires were distributed and 349 received(52.6% response rate). Of 340 eligible respondents, 221(65%) would continue 5ASA in a patient hospitalized for intravenous CS treatment due to a moderate-severe UC flare, while 108(32%) would stop the 5ASA(P < 0.001), and 11(3%) are undecided. Similarly, 62% would continue 5ASA in an out-patient starting oral CS. However, only 140/340(41%) would proactively start 5ASA in a hospitalized patient not receiving 5ASA before admission. Most(94%) physicians consider the safety profile of 5ASA as very good. Only 52% consider them inexpensive, 35% perceive them to be expensive and 12% are undecided. On multi-variable analysis, less years of practice and perception of a plausible additive mechanistic effect of 5ASA + CS were positively associated with the decision to continue 5ASA with CS. CONCLUSION Despite the absence of data supporting its benefit, most gastroenterologists endorse combination of 5ASA + CS for patients with active moderate-to-severe UC. Randomized controlled trials are needed to assess if 5ASA confer any benefit for these patients. | Shomron Ben-Horin Jane M Andrews Konstantinos H Katsanos Florian Rieder Flavio Steinwurz Konstantinos Karmiris Jae Hee Cheon Gordon William Moran Monica Cesarini Christian D Stone Doron Schwartz Marijana Protic Xavier Roblin Giulia Roda Min-Hu Chen Ofir Har-Noy Charles N Bernstein | 2017 | World Journal of Gastroenterology2017，23，16： | 3 |
| 4 | Management of cytomegalovirus infection in inflammatory bowel diseases显示文摘 | Sylvie Pillet Bruno Pozzetto Camille Jarlot Stéphane Paul Xavier Roblin | 2012 | Digestive and Liver Disease2012，，7： | 2 |
| 5 | Adalimumab induction therapy for ulcerative colitis with intolerance or lost response to infliximab: An open-label study显示文摘AIM: To evaluate the efficacy of adalimumab induction therapy in patients with ulcerative colitis who previously responded to infliximab and then lost response or became intolerant. METHODS: Ten patients with ulcerative colitis were enrolled in a 4-wk open-label trial. The patients received a loading dose of 160 mg adalimumab at wk 0 followed by 80 mg at wk 2. The primary efficacy measure was clinical improvement at wk 4, as defined by a decrease in clinical activity index (CAI) of more than 4. RESULTS: Four of 10 patients (40%) benefited from subsequent adalimumab therapy; one patient achieved remission (CAI < 4) and 3 had clinical improvement at wk 4. 6 patients had no response (60%); 2 of 6 (33.3%) subsequently underwent colectomy. This was accompanied by a decrease in median CRP concentration from 16.8 mg/mL at baseline to 3.85 mg/mL at wk 4, excluding two patients who underwent colectomy after two infusions of adalimumab. Among the 6 patients with severe colitis (CAI > 12) at baseline, none achieved remission and only one patient had clinical improvement at wk 4. CONCLUSION: The small advantage of adalimumab in patients with mild to moderate ulcerative colitis and lost response or intolerance to infliximab needs to be confirmed in randomised, double-blind, placebo- controlled trials. | Laurent Peyrin-Biroulet Cécile Laclotte Xavier Roblin Marc-André Bigard | 2007 | World Journal of Gastroenterology2007，13，16： | 2 |
| 6 | Ultraviolet light propagation under low visibility atmospheric conditions and its application to aircraft landing aid显示文摘 | LAVIGNE C DURAND G ROBLIN A | 2006 | Applied Optics2006，45，36： | 1 |
| 7 | Generation of hair cells by stepwise differentiation of embryonic stem cells显示文摘 | LI H ROBLIN G LIU H | 2003 | Proc Natl Acad Sci USA2003，100，13： | 1 |
| 8 | lntemal mammary artery perforator (IMAP) flap for traeheostoma reconstruction 显示文摘 | Yu P Roblin P Chevray P | 2006 | Head Neck2006，28，8： | 1 |
| 9 | Factors affecting post -operative complications following skin sparing mastectomy with immediate breast reconstruction 显示文摘 | Davies K Allan L Roblin P | 2011 | Breast2011，20，1： | 1 |
| 10 | A comparative analysis of international frameworks for 21st century competences : Implications for national curriculum policies 显示文摘 | Joke Voogt Natalie Pareja Roblin | 2012 | Curriculum Studies2012，，： | 1 |
| 11 | UV missile plume signatures model显示文摘 | Roblin Antoine Baudoux Pierre E Chervet Patrick | 2002 | SPIE2002，4718，： | 1 |
| 12 | Internal mammary artery perforator (IMAP) flap for tracheostoma reconstruction 显示文摘 | Yu P Roblin P Chevray P | 2006 | Head Neck2006，28，8： | 1 |
| 13 | Asymptomatic respiratory tract infection with Chlamydia pneumoniae TWAR显示文摘 | Hyman CL Augenbraun MH Roblin PM | 1991 | J Clin Microbiol1991，29，： | 1 |
| 14 | Validity of sleep nasendos- copy in the investigation of sleep related breathing disorders 显示文摘 | Berry S Roblin G Williams A | 2005 | Laryngoscope2005，115，3： | 1 |
| 15 | Simulation of hot-electron trapping and aging of nMOSFET's显示文摘 | Roblin Patrick Samman Amer | 1988 | IEEE Transaction on Electron Device1988，35，12： | 1 |
| 16 | The association of Chlamydia pneumoniae infection and reactive airway disease in children显示文摘 | Emre U Roblin PM Gelling M | 1994 | Arch Pediatr Adolesc Med1994，148，7： | 1 |
| 17 | Tofacitinib in colitis显示文摘 | Paul S Roblin X active ulcerative of medicine 2012 Sandborn WJ | 1959 | The New England journal1959，367，20： | 1 |
| 18 | Primary biliary cirrhosis显示文摘 | Roblin X Bonaz B | 2005 | N Engl J Med2005，353，： | 1 |
| 19 | How does premature ejaculation impact a man life? 显示文摘 | Symonds T Roblin D Hart K | 2003 | J Sex Mar Ther2003，29，： | 1 |
| 20 | How does premature ejaculion impact a mang life显示文摘 | Symonds T Roblin D Hart K | 2003 | J Sex Marital Ther2003，29，5： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员